Nurix Therapeutics, Inc.
Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Employees
284
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
1700 Owens Street, San Francisco, CA 94158, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 9, 2025 | — | — | — | — |
| Jul 9, 2025 | — | — | — | — |
| Apr 8, 2025 | — | — | — | — |
| Feb 13, 2025 | -0.67 | — | — | — |
| Oct 12, 2024 | -0.71 | -0.67 | 0.04 | -5.63% |
Earnings estimate
|
Next Quarter
(Feb 2025)
|
Next Year
(Nov 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 8 | — | 13 |
| Average estimate | — | -0.68 | — | -2.74 |
| Low estimate | — | -0.76 | — | -3.33 |
| High estimate | — | -0.62 | — | -1.96 |
| Last year EPS | — | -0.76 | — | -2.77 |
[stock_revenue_estimate]
Growth estimates
Current qtr
1.640%
Next qtr. (Feb 2025)
-6.640%
Current year
-7.400%
Next year (Nov 2025)
-2.690%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 |
| Total reported revenue | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 221.63M | 189.15M | 184.50M | 116.43M | 66.49M |
| Selling general and admin | 45.94M | 42.90M | 38.00M | 31.20M | 16.31M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -213.03M | -155.06M | -183.87M | -117.89M | -64.98M |
| Non operating interest income | |||||
| Income | 19.73M | 11.12M | 3.51M | 823,000 | 1.21M |
| Expense | — | — | — | — | — |
| Other income expense | — | — | — | — | — |
| Pretax income | -193.30M | -143.95M | -180.36M | -117.06M | -63.78M |
| Tax provision | 270,000 | — | — | 131,000 | -20.54M |
| Net income | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M |
| Basic EPS | — | -2.65 | -3.71 | -2.73 | -2.76 |
| Diluted EPS | — | -2.65 | -3.71 | -2.73 | -2.76 |
| Basic average shares | — | 54.34M | 48.61M | 42.90M | 15.67M |
| Diluted average shares | — | 54.34M | 48.61M | 42.90M | 15.67M |
| EBITDA | -196.60M | -141.41M | -173.06M | -111.80M | -62.80M |
| Net income from continuing op. | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 |
| Total assets | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M |
| Other short term investments | 499.59M | 233.28M | 244.67M | 215.21M | 161.79M |
| Accounts receivable | — | — | — | 6.00M | — |
| Other receivables | — | — | — | — | 7.50M |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | — | 9.19M | 5.94M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 9.80M | 7.60M | 9.31M | 9.19M | 5.94M |
| Non current assets | |||||
| Properties | 67.17M | 63.38M | 38.73M | 32.33M | 14.12M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 7.59M | 6.99M | 5.93M | 4.32M | 3.07M |
| Construction in progress | 497,000 | 587,000 | 697,000 | 491,000 | — |
| Leases | 5.14M | 3.24M | 3.83M | 3.08M | 2.66M |
| Accumulated depreciation | -34.50M | -26.25M | -19.67M | -14.88M | -13.18M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | 7.42M | 63.88M | 137.19M | 90.89M |
| Other non current assets | 4.06M | 4.72M | 4.92M | 3.12M | 347,000 |
| Total liabilities | 142.35M | 155.11M | 113.06M | 134.47M | 106.07M |
| Current liabilities | |||||
| Accounts payable | 11.48M | 6.40M | 5.06M | 6.65M | 3.41M |
| Accrued expenses | 17.85M | 8.89M | 7.68M | 4.96M | 1.83M |
| Short term debt | 8.01M | 7.49M | 5.53M | 3.85M | — |
| Deferred revenue | 38.36M | 48.10M | 37.63M | 41.21M | 32.80M |
| Tax payable | 1.24M | 30,000 | 85,000 | 75,000 | 74,000 |
| Pensions | 16.63M | 15.30M | 13.16M | 8.85M | 5.73M |
| Other current liabilities | 2.28M | 751,000 | 1.50M | 659,000 | 700,000 |
| Non current liabilities | |||||
| Long term debt | 20.29M | 23.13M | 6.43M | 9.19M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | 850,000 |
| Shareholders equity | |||||
| Common stock | 76,000 | 49,000 | 47,000 | 45,000 | 39,000 |
| Retained earnings | -738.77M | -545.20M | -401.25M | -220.89M | -103.70M |
| Other shareholders equity | 150,000 | -655,000 | -4.32M | -608,000 | 87,000 |
| Total shareholders equity | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M |
| Additional paid in capital | 1.27B | 746.30M | 709.22M | 563.76M | 393.84M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M | -21.70M | -9.43M |
| Depreciation | 16.43M | 13.65M | 10.81M | 6.08M | 2.18M | 2.35M | 2.99M |
| Deferred Taxes | — | — | — | — | — | — | — |
| Stock-Based Compensation | 33.93M | 33.67M | 28.13M | 15.80M | 4.30M | 510,000 | 431,000 |
| Other Non-Cash Items | 286,000 | — | 201,000 | — | — | — | -6,000 |
| Accounts Receivable | — | — | 6.00M | -2.36M | -11.35M | — | 12.37M |
| Accounts Payable | 5.21M | 1.61M | 85,000 | 1.59M | 1.23M | 302,000 | -519,000 |
| Other Assets & Liabilities | -34.97M | 13.25M | -31.50M | 9.11M | 48.18M | 16.89M | -37.45M |
| Operating Cash Flow | -172.68M | -81.76M | -166.63M | -86.98M | 1.31M | -1.65M | -31.61M |
| Investing Activities | |||||||
| Capital Expenditures | -9.27M | -8.40M | -12.24M | -5.66M | -4.55M | -1.65M | -1.59M |
| Net Intangibles | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — |
| Purchase of Investments | -707.95M | -246.33M | -239.37M | -348.50M | -275.22M | -9.35M | -12.92M |
| Sale of Investments | 459.51M | 323.04M | 278.81M | 245.91M | 25.37M | 19.50M | 54.50M |
| Investing Cash Flow | -257.71M | 68.30M | 27.20M | -108.25M | -254.40M | 8.50M | 39.99M |
| Financing Activities | |||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | -7,000 | -16,000 | -2,000 |
| Financing Cash Flow | 478.50M | — | 19.40M | 150.16M | 338.05M | -16,000 | -2,000 |
| Other Cash Details | |||||||
| End Cash Position | 110.90M | 55.53M | 65.38M | 80.79M | 119.53M | 34.99M | 25.76M |
| Income Tax Paid | — | — | — | 481,000 | 1,000 | 1,000 | 1,000 |
| Interest Paid | — | — | — | — | — | — | — |
| Free Cash Flow | -181.86M | -89.77M | -172.05M | -90.03M | -4.63M | -1.05M | -33.27M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,128,355 | 40.86M | 2.80% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,790,843 | 34.38M | 2.36% |
| ARK ETF Tr-ARK Genomic Revolution ETF | Nov 30, 2024 | 1,644,368 | 31.57M | 2.17% |
| Price (T.Rowe) New Horizons Fund | Sep 30, 2024 | 1,453,367 | 27.90M | 1.92% |
| Fidelity Select Portfolios - Health Care | Nov 30, 2024 | 1,285,000 | 24.67M | 1.69% |
| Fidelity Select Portfolios - Biotechnology | Nov 30, 2024 | 1,141,946 | 21.93M | 1.50% |
| Fidelity Advisor Biotechnology Fund | Nov 30, 2024 | 1,036,600 | 19.90M | 1.37% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 1,021,783 | 19.62M | 1.35% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 909,285 | 17.46M | 1.20% |
| Fidelity Advisor Health Care Fund | Nov 30, 2024 | 800,000 | 15.36M | 1.05% |
Article
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 12:40 p.m. ET.
Feb 4, 2025
Article
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.77 per share a year ago.
Jan 28, 2025
Article
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
R eported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66 th American Society of Hematology Annual Meeting
Jan 28, 2025
